Cardinal Health is a global healthcare services and products company that plays a vital role in the medical supply chain. It specializes in the distribution of pharmaceuticals and medical supplies to healthcare institutions, pharmacies, and patients. In addition to its distribution services, the company also manufactures and provides a wide range of medical and surgical products, including surgical gloves, apparel, and other healthcare-related items. Cardinal Health is committed to enhancing patient care by ensuring the availability of essential products and services, while also striving to improve the efficiency and effectiveness of healthcare delivery across various settings. Read More
McKesson Corporation (NYSE: MCK) stands today as the undisputed titan of the U.S. pharmaceutical supply chain. While the company has long been a staple of the Fortune 500, its relevance has surged in early 2026 as it navigates a complex landscape of drug shortages, revolutionary new therapies, and a massive internal restructuring. The company is [...]
Healthcare distributor and services company Cardinal Health (NYSE:CAH) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 18.8% year on year to $65.63 billion. Its non-GAAP profit of $2.63 per share was 11.2% above analysts’ consensus estimates.
Shares of healthcare distributor and services company Cardinal Health (NYSE:CAH)
jumped 10.1% in the afternoon session after the company reported better-than-expected fourth-quarter financial results and raised its full-year earnings guidance.
Healthcare distributor and services company Cardinal Health (NYSE:CAH) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 18.8% year on year to $65.63 billion. Its non-GAAP profit of $2.63 per share was 11.2% above analysts’ consensus estimates.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising
as the industry has posted a 22% gain over the past six months, beating the S&P 500 by 14.2 percentage points.
Wall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
The global healthcare landscape shifted decisively on December 16, 2025, with the public market return of Medline Industries (Nasdaq: MDLN). After four years under the stewardship of a private equity consortium—and decades of private family ownership before that—the medical supply titan has reclaimed its status as a public entity in the largest U.S. initial public [...]
CRANFORD, NJ — As the 2025 calendar year draws to a close, Citius Oncology, Inc. (Nasdaq: CTOR) has reached a pivotal juncture in its corporate evolution. Following the release of its SEC 10-K filing for the fiscal year ended September 30, 2025, the company has officially shed its "development-stage" label, entering
In a stunning return to the public stage, Medline Industries (Nasdaq: MDLN) successfully executed the largest initial public offering (IPO) in the United States since 2021, pricing its shares at the top of its range and witnessing a massive first-day "pop" that has sent ripples through the financial world. The
Looking back on healthcare providers & services stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Cardinal Health (NYSE:CAH) and its peers.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
